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Exhaled nitric oxide in cystic ¢brosis patients with
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Abstract
Exhalednitricoxide (NO) is thoughtto be amarkerof asthmatic inflammation.Levels in cystic fibrosis (CF) are generally
low.This study aimed tomeasure exhaled NOin CF patients at high riskof developing ABPA andpatients at lowrisk.We
studiednine patients athighriskof developing ABPA and 36 at lowrisk.The two groupswere similar in age and spirome-
try.Allpatientsinthehigh-riskgroupweretakingoralor inhaledglucocorticoids, comparedto 56% inthe low-riskgroup
(P=0.02).The exhaled NO levels were lower in the high-risk group than in the low-risk group (2.0 vs. 3.6 ppb), mean
difference (95% CI) 1.6 (3.6 to 0.4) ppb, P=0.001.On subgroup analysis of patients on oral glucocorticoids, the exhaled
NOlevelswere significantlylowerinpatientswith ahighriskofdevelopingABPA (n=7) thanpatientswith alowrisk (n=8)
(P=0.011).The number of patients who were on inhaled, but not oral glucocorticoids was too small to analyse usefully.
Exhaled NO levels were lower in CF patients with a high risk of developing ABPA and on glucocorticoids.This may be
because oral glucocorticoids exert a greater effect on exhaled NO than inhaled glucocorticoids. Alternatively, inducible
nitric oxide synthasemaybe down-regulatedby Aspergillus toxin.r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1430, available online at http://www.sciencedirect.com
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Nitric oxide (NO) is excreted in the exhaled breath of
humans and other mammals (1). It is an important med-
iator inmany organ systems. In the lung, itmediatesmu-
cosal in£ammatory responses, airway smooth muscle
contractility, and pulmonary vasodilatation (2). Central
to the formation of NO and its reactive nitrogen pro-
ducts is the enzyme nitric oxide synthase (NOS) which
has been characterised in almost all the cells within the
airways (3). Several forms of NOS have been described
and an inducible form (iNOS) can be up-regulated by in-
£ammatory cytokines (4). As a result, NO concentra-
tions in exhaled breath have been suggested as being
useful in monitoring disease activity in in£ammatory air-
way diseases, particularly in asthma. Exhaled NO con-
centrations are particularly raised in patients with
atopic or allergic asthma (5^7), but are not raised in pa-
tients with cystic ¢brosis (CF) or bronchiectasis (8,9).Received 26 October 2001, accepted in revised form1August 2002.
Correspondence should be addressed to:Dr Albert Y.H.Lim,
Department of Respiratory Medicine,Heartlands and Solihull Hospital
NHS Trust, Bordesley Green East, Birmingham B9 5SS,UK.Fax: +44
121772 0292; E-mail: alim@medix-uk.comAllergic bronchopulmonary aspergillosis (ABPA) is a
hypersensitivity reaction to Aspergillus fumigatus (Af ),
which was ¢rst described in 1952 (10). CF patients may
be prone to colonisation with Af because of their very
tenacious sputum.Untreated ABPAmay lead to lung da-
mage, including proximal bronchiectasis and segmental,
lobar or whole lung collapse, and it is di⁄cult to di¡er-
entiate this damage from that due to CF itself.
Given the allergic nature of ABPA and the presence of
normal levels ofNO in the exhaledbreath of CF patients,
wehypothesised thatexhaledNOmayprove tobe ause-
fulmarker of thepresence of an allergic airwaydisease in
this group of patients. The levels of exhaled NO were
studied in CF patients at high risk of developing ABPA




We studied 45 adult patients with CF (mean (7SE) age
25.871.1 years, 22 female). The patients were recruited
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lands Hospital. None were cigarette smokers or had a
history of asthma. All participants gave their written
consent, having been fully informed of the nature, risks
and potential bene¢ts of the study.The study was obser-
vational andwas approvedby the East BirminghamLocal
Research and Ethics Committee.
Study design
Patients were interviewed at routine CF clinics or as in-
patients if they were receiving in-patient treatment.
Data were obtained during the interview and from the
case notes. Age, sex, height,CF genotype and glucocor-
ticoid therapy (both inhaled and oral) were recorded.
Peripheral venous blood was taken for measurement of
total IgE, speci¢c IgE to timothy grass pollen, house dust
mite, cat dander, mixed moulds, Cladosporium herbarum
and Af. The peripheral eosinophil count and serum
precipitating antibody to Af were also measured by an
immuno-di¡usion technique. Spirometry was per-
formed using a dry bellows spirometer (Vitalograph,
Buckingham, U.K.), using the best of three reproducible
measures.
De¢nitionOFABPA
In this study, we categorised our patients into two
groups: (1) CF patients at high risk of developing ABPA
and (2) CF patients at low risk of developing ABPA.We
de¢nedpatients athighriskof developingABPA ashaving
(i) elevated speci¢c IgE antibodies (RAST score 42) to
Af, with (ii) an increased level of total serum IgE
o500KU/l or a recent doubling in the level of the serum
total IgE above 200KU/l, and (iii) reduced lung function
on at least one occasion responding to oral steroids, but
not to intravenous antibiotics over a 5-year period. Pa-
tients who did not ful¢l the above criteria were consid-
ered as low risk of developing ABPA.This was based on
the suggestions that high absolute level of speci¢c IgE to
Af (11^13) and a raised serum total IgE herald the onset of
ABPA (13^15).
Nitric oxide excretionmeasurements
All exhaled NO was measured at least 6 h after inhaled
steroids. Concentrations of NO in the exhaled breath
were measured using a chemi-luminescence analyser
(LR2000, Logan Research, Rochester, Kent, U.K.). The
analyser was calibrated daily against a known standard
(99parts per billion (ppb)), sampling at 25Hz in real time
with a sensitivity of 0.3 ppb.Concentrations of NO in the
exhaled breath representative of concentrations in the
lower respiratory tract weremeasured during three se-
parate exhalations with the subject exhaling at 200ml/sagainstresistance, using avisual feedbackdisplay tomain-
tain constant £ow. The analyser sampled from the
streamusing a side arm and lower respiratory tract sam-
ples were assessed when 75% of the vital capacity had
been exhaled (16). Typical values with this technique in
normal subjects are 5 ^ 10ppb.Thewithin subject co-ef-
¢cientof variation is approximately10%when singlemea-
surements are made (17,18). The mean of three
measurementswas therefore taken tominimise this var-
iation.
Statistics
Demographic details are presented using summary sta-
tistics. Categorical variables were compared using chi-
squared analysis or Fisher’s exact test. If data were nor-
mally distributed, unpaired t-tests were used, and if non-
normal, the Mann^Whitney rank sum test was used to
assess the di¡erences in demographic details, lung func-
tion, blood results and exhaled NO concentrations be-
tween the two groups. For all tests, P o0.05 was used
to de¢ne a statistically signi¢cant result.
RESULTS
NineCF patientswith a high risk and 36CF patientswith
a low risk of developing ABPA as a control group were
identi¢ed.The groups’ characteristics are summarised in
Table 1. All were non-smokers and none of the patients
were taking antifungal treatment at the time of study.
The two groups were similar in age, sex distribution,
and spirometric lung function. Three of the nine (33%)
patients in the high-risk group were homozygous for
DF508 for the CF transmembrane conductance regula-
tor (CFTR) mutation and another threewere heterozy-
gous for DF508. Fifteen of the 36 (42%) patients in the
low-risk group were homozygous for DF508 for the
CFTR and another 15 were heterozygous for DF508.
The CFTR mutation was non-detected in two patients
in the high-risk group and one in the low-risk group.No
di¡erences were observed in the number of patients
with sputum colonised by Pseudomonas aeruginosa,
Staphylococcus aureus and upper respiratory £ora
or no growth. Two of the nine patients with a high risk
of developing ABPA had precipitating antibodies to Af,
which is consistent with previous work (18). The mean
peripheral eosinophil counts between the groups were
similar.
Seventy-eight per cent of the CF patients with a high
riskof developingABPAwere sensitised tomixedmoulds
and 33% in the low-risk group (P=0.02). Similarly, 78% of
the patients in the high-risk group were sensitised to C.
herbarum and 100% to Af (Po0.0001 and 0.006, respec-
tively). No statistically signi¢cant di¡erence was noted
in the number of patients sensitised to grass pollen, cat
TABLE 1. Characteristics of CF patientswith a highrisk (n=9) and CF patientswith a lowriskof developing ABPA (n=36)
High-riskgroup (n=9) Low-riskgroup (n=36) P value
Age (years): mean (range) 25.1 (18^39) 26.0 (17^45) 0.75
Sex:Male/Female 7/2 16/20 0.14
Predicted FEV1 (%): mean (SE) 43.8 (4.7) 53.6 (3.7) 0.26
Predicted FVC (%): mean (SE) 70.3 (7.1) 74.6 (4.2) 0.65
IgE (KU/l): mean (SE) 786.1 (147.1) 165.4 (41.8) o0.0001
Patientswith precipitatingantibodies
to Af: number (%)
2 (22%) 2 (6%) 0.18
Peripheral eosinophil count ( 109/l):
mean (range)
0.16 (0^0.5) 0.14 (0^0.6) 0.98
Patients receiving glucocorticoids
(either inhaled ororal): number (%)
9 (100%) 20 (56%) 0.01
Totalprednisolone dosage perday (mg/day):
median (range)
15.0 (5^20) (n=7) 12.5 (5^20) (n=8) 0.64
Totalbeclometasone dipropionate (BDP)
equivalentdosage perday (mcg/day) :
median (range)
900 (800^1000) (n=2) 1000 (800^4000) (n=12) 0.30
Exhalednitric oxide (ppb): median (range) 1.8 (1.4^3.2) 2.9 (1.2^18.0) 0.001











FIG. 1. ExhaledNOlevelsinpatientswithahighriskof develop-
ing ABPAandonoralglucocorticoids (group1),CF patientswith a
low risk of developing ABPA and on oral glucocorticoids (group
2), and CF patients with a low risk of developing ABPA and not
onglucorticoids (group 3).Horizontalbarsdenotemedianvalues.
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CF patientswith a high riskof developing ABPA, but only
56% of the low risk patients, were taking either oral or
inhaled glucocorticoid medication. None of the patients
were taking any antifungal agent (e.g. itraconazole) at
the time of this study.
The concentration of NO in the exhaled breath was
lower in the high-risk group (n=9) than in the low risk
group (n=36), 2.0 ppb vs. 3.6ppb, mean di¡erence (95%
CI) 1.6 (3.6 to 0.4) ppb, P=0.001 (Table 1).On subgroup
analysis of patients who were on oral glucocorticoids,
the exhaled NO was signi¢cantly lower in CF patients
at high risk of developing ABPA (n=7) than patients of
low risk (n=8), 2.0 vs. 3.1ppb, mean di¡erence (95% CI)
1.1 (1.8 to0.5) (P=0.011) (Fig.1).For patients who were
taking inhaledglucocorticoids, therewas no di¡erence in
exhaled NO between the high-risk (n=2) and low risk
groups (n=12) (2.0 vs. 3.4 ppb).
DISCUSSION
The diagnosis of ABPA in CF patients is di⁄cult as the
signs and symptoms of ABPA are similar to those of CF.
Patients with ABPA usually develop the disease in child-
hood, but it often remains undiagnosed for many years
(19). One study reported that the diagnosis was made
on an average of10 years following the ¢rst symptom of
ABPA (20).The disease can progress insidiously to its la-
ter stages, while there is no characteristic clinical mani-
festation. An easily used, sensitive and speci¢c test for
this serious disease is needed.The ‘‘gold standard’’ diagnostic criteria for ABPA ac-
cording toNelson et al. (21) are (i) pulmonary in¢ltration
radiologically, (ii) wheezing, (iii) positive sputum culture
for Af, (iv) positive immediate reaction to Af in skin prick
testing, (v) increased level of serum total IgE, (vi) in-
creased level of speci¢c IgE to Af, and (vii) presence of
precipitating antibody to Af.Greenberger and Patterson
described that ¢ve criteriawere considered to be essen-
tial, namely asthma, positive immediate skin test to
Af, IgE of41000ng/ml, precipitating antibody to Af and
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elevated IgG, IgE antibodies and central bronchiectasis
were highly speci¢c for ABPA (12). An earlier study by
Rosenberg et al. described the case histories, diagnostic
criteria, immunologic and radiographic ¢ndings of 20 pa-
tients with de¢nite or possible ABPA. Total serum IgE
above 1000ng/ml was found in 19 of the 20 cases. The
authors argued that an elevation of total IgE is not
pathognomonic for ABPA, as it has been found in other
conditions such as atopic dermatitis and atopic asthma.
They did not include patients with CF in their study
(22). A recent study of CF patients with ABPA by Skov
et al. (13) showed that a total serum IgE level above
200KU/l is associatedwith an 80%positivepredictive va-
lue and a 100% negative predictive value for diagnosing
ABPA. A total serum IgE level above 500KU/l has also
been describedbyMarchantetal. (14) as strongly sugges-
tive of the diagnosis of ABPA in children with CF.
Furthermore, a doubling of the total IgE was suggested
by Greenberger (15) as being su⁄cient to signal the on-
set of ABPA.Consequently, webelieve our diagnostic ap-
proach to diagnosis is robust and justi¢ed.
Patients with CF have a high prevalence of atopy.This
has been con¢rmed by us (23) and others (21,24,25).This
can raise the level of total serum IgE, so that a cuto¡ of
41000nm/l is neither speci¢c nor sensitive for the diag-
nosis of ABPA in patients with CF. For these reasons,
there is a risk of confusion and delay in making this im-
portant diagnosis in CF.Therefore, we used a combina-
tion of: raised total serum IgE above 500KU/l or a
recent doubling in the level of total serum IgE above
200KU/l; raised speci¢c IgE (RAST 42) to Af; and re-
duced lung function on at least one occasion responding
to oral steroids, but not intravenous antibiotics over
a 5-year period to identify patientswith a high riskof de-
veloping ABPA. In CF, pulmonary in¢ltrates, wheezing
and bronchiectasis are common. Precipitating antibody
to Af is present in CF with or without ABPA (26,27,38).
It may vary with time and can disappear spontaneously
(38). This may be due to technical reasons such as
the potency of Af antigen and the experience of techni-
cians (28).
Exhaled NO concentrations are particularly raised in
allergic airway diseases such as atopic asthma (5), while
concentrations of NO in the breath of CF patients are
typically low (8). Since ABPA is a hypersensitivity lung
disease induced in individuals previously exposed to Af
(29), we hypothesised that concentrations of exhaled
NOmayberaised inCF patientswith a high riskof devel-
oping ABPA. In this study, we have shown that exhaled
NO levels were signi¢cantly lower in patients at high
risk of developing ABPA compared to a demographically
similar group of CF patients at low risk of developing
ABPA.
No signi¢cant di¡erence was observed between the
high-risk and low-risk groups in their % predicted FEV1.Although various studies have shown thatwithin an indi-
vidual exhaled NO declines with bronchoconstriction
(30^32), no such e¡ect has been noted with regard to
FEV1between individuals.Changes in FEV1can therefore
not explain our ¢ndings.
The high-risk group had a signi¢cantly higher preva-
lence of sensitisation to mixed moulds,C. herbarum and
Af (78, 78 and 100%, respectively), but the exhaled NO
level was signi¢cantly lower than the low-risk group.
However, the use of glucocorticoids was universal in the
ABPA group with only half of the control group using
these agents.
There are a number of potential explanations for
these ¢ndings.Firstly, theremaybe a decrease in produc-
tion of NO due to inhibition of iNOSby Aspergillus toxin.
This is supportedby the inhibition of the oxidative burst
in alveolarmacrophagesby an Af di¡usate toxin (33). Sec-
ondly, NO in the exhaled breath is predominantly pro-
duced by the epithelium. Since ABPA is characterised by
damage to the airway epithelium, this could also explain
our ¢ndings.Thirdly, the airway epithelial cells in patients
with ABPAmay have a reduced expression of iNOS due
to a lower functionalCFTR activity than inpatientswith-
out ABPA. Absence of functional CFTR may lead to a
change in cell signalling events which alters the expres-
sion of iNOS (34,35). Finally, it has been demonstrated
that ABPA is associated with an antigen-speci¢c TH2
lymphocyte immune response, as indicated by excessive
IL-4 and IL-5 secretion in ABPA (36). This could explain
our ¢ndings, as IL-4 inhibits the induction ofmacrophage
NO synthase (37).
Subgroup analysis onpatientswhowere on oral gluco-
corticoid therapy showed that the exhaled NO levels
were signi¢cantly lower in CF patients with a high risk
of developing ABPA than patients with a low risk. The
group of patients, who were on inhaled, but not on glu-
cocorticoid therapy was too small to analyseusefully. All
exhaledNOwasmeasuredat least 6 h after their inhaled
steroids and hence this potential factor has been ex-
cluded in this study. The number of patients in the
high-risk group and the low-risk group who used
inhaled steroids were 22% (2/9) and 33% (12/36), respec-
tively. No di¡erence was observed in the total beclo-
methasone dipropionate dosage between the two
groups (P=0.3). Therefore, the low exhaled NO level in
the high-risk group cannot be attributed to the inhaled
steroids.
The ¢nding that patients with ABPAwere more likely
to be sensitised to mixed moulds and C. herbarum con-
¢rmed that patients with CF show a high reactivity to
aeroallergens as described by Becker et al. (24). It has re-
cently been suggested that atopy is a risk factor for the
developmentof ABPA inCF patients (23,36), which led to
the postulate that patients with CF and ABPA are more
prone to sensitisation to fungal aeroallergens than pa-
tients without ABPA.
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exhaled breath was signi¢cantly lower in CF patients
with a high riskof developingABPA andon oral glucocor-
ticoid therapy compared to those at low risk also taking
oral steroids. This may be explained by oral glucocorti-
coids having a greater e¡ect on exhaledNO than inhaled
glucocorticoids, or by inhibition of iNOS by Aspergillus
toxin in these individuals. The measurement of exhaled
NOmeasurement is a non-invasive and straightforward
procedure.The equipment required to perform this test
is becoming more user friendly and more widely avail-
able. As the current diagnostic criteria for ABPA in pa-
tients with CF are neither speci¢c nor sensitive,
improvedmarkers arerequired in order to prevent delay
inmaking this important diagnosis in CF patients.To this
end, the measurement of exhaled NO may be a useful
supplementary test. A prospective study on exhaled
NO levels in CF patients with a high risk of developing
ABPA is required to con¢rm the usefulness of exhaled
NO inmonitoring the activities of ABPA in this group of
patients.
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